New regulations on online sales of drugs clarify the management of online sales of prescription drugs
Recently, the State Administration for Market Regulation issued the Measures for the Supervision and Administration of Online Drug Sales (Order of the State Administration for Market Regulation No. 58), which will come into force on December 1, 2022.
The CPC Central Committee and the State Council attach great importance to the responsibility of drug safety, which concerns people's lives and health. To implement the party central committee and state council on drug regulatory "four most strict requirements and a series of policy decisions, refinement, with the pharmaceutical administration law of the provisions of the drug sales network as a whole the convenience to buy medicine and drug safety supervision, to ensure the public safety and legitimate rights and interests, market supervision administration, food and drug administration on the basis of in-depth study, completely demonstrated, Measures for the Supervision and Administration of Online Drug Sales have been formulated. The Measures, consisting of six chapters and 42 articles, stipulate the management of online drug sales, platform responsibility fulfillment, supervision and inspection measures, and legal liabilities. Major articles included:
First, the principal responsibility of drug distributors should be enforced..The qualifications and requirements of drug distributors engaged in online drug sales shall be clarified, and drugs under the special administration of the State, such as vaccines, blood products, narcotic drugs, psychotropic drugs, toxic drugs for medical use, radioactive drugs and pharmaceutical precursor chemicals, shall not be sold online..At the same time, the whole process of drug operation management should be strictly implemented, and clear requirements should be put forward for the whole process management of online drug sales enterprises, such as quality and safety management system, pharmaceutical care, drug storage and distribution, drug traceability, risk control and information disclosure.
The second is the responsibility of online sales platforms for condensed pharmaceuticals. Clear the third-party platform should be establish drug quality and safety management agencies, with pharmaceutical technical personnel, establish and implement quality and safety of drugs, pharmaceutical information display, prescription audit, prescription medication real-name, drug delivery, transaction records, adverse reaction reports and complaints to report, management system, and in accordance with the provisions, for the record. At the same time, the platform and network sales enterprises signed an agreement, both the quality and safety responsibility precisely, platform shall perform the audit, inspection monitoring and stop service and report found serious violations of the obligations, and strengthen the platform in drug recall, emergency disposal and the supervision and inspection of the obligation.
Third, clear management of online sales of prescription drugs..Considering the medication safety risks and the online and offline consistency management requirements, the real name system for online prescription drug sales should be precisely implemented, and prescriptions should be reviewed and allocated according to regulations..Prescription and over-the-counter drugs should be displayed separately, and it should be made clear that packaging, labels and additional information should not be displayed directly on the front page and home page where prescription drugs are sold;; before passing the prescription review, no information such as instructions shall be displayed, and no services related to prescription drug purchase shall be provided, aiming to emphasize the management requirements of "prescription before medicine" and prescription review. At the same time, consumers should be thoroughly informed of relevant risk warning information and confirmed by consumers before prescription drugs are sold to effectively prevent drug safety risks.
Fourth, implement the "four strictest" requirements and strengthen the supervision measures of regulatory departments at all levels. It clarifies the responsibility division of drug regulatory departments at all levels in the supervision of online drug sales and the jurisdiction to investigate and deal with illegal acts, requires strengthening the monitoring of online drug sales, and investigates and handles illegal acts found by monitoring according to law and duties. To strengthen the control of drug safety risks, if there is evidence that there may be hidden safety risks, it is clear in accordance with the law that drug regulatory authorities can take measures such as warning, interview, rectification within a specified time limit, and suspension of production, sale, use and import. In addition, the Measures clarify the corresponding legal liability for illegal online drug sales.
Looking for chemical products? Let suppliers reach out to you!
2026-06-27
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Alchem Fined $576,000 for Role in EU Pharmaceutical Cartel
-
Sipcam Nichino Brasil Unveils Soleado Fungicide at Hortitec 2025
-
Pharma Companies to See 11 Percent Growth in Sales and EBITDA in Q1FY26
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
Recommend Reading
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
The relationship between Digital Transformation and Work- Life Balance in the Egyptian Pharmaceutical Industry
-
This week, the market price of propylene oxide in China has increased (11.3-11.6)
-
This Week's Epichlorohydrin Market Trading Focus Downward (11.3-11.6)
-
Business Society: Bisphenol A Market to Stabilize First, Then Strengthen in January 2026
-
“Milk Sugar 2.0” Cleared for Takeoff: EU Greenlights Next-Gen Human-Identical Oligosaccharide for Infant Nutrition